Jam

Eli Lilly will turn Huntsville, Alabama into the domestic hub for small‑molecule and peptide API production, investing more than $6 billion in a next‑generation facility that will manufacture its first oral GLP‑1 agonist, orforglipron. Construction begins in 2026, creating about 3,000 temporary jobs, and the plant—set to finish in 2032—will support 450 high‑skill positions. The site employs AI‑driven automation, aims for carbon‑neutral operations, and complements Lilly’s broader U.S. expansion to bolster supply‑chain resilience and domestic drug manufacturing.

Microsoft’s 2025 annual meeting saw shareholders reject Proposal 9—a BDS‑linked resolution targeting Israel—by over 70% of votes. JLens and the ADL praised the outcome, noting the proposal’s political motive contrary to fiduciary duty. More than 50 shareholders co‑filed the measure, with Norway’s GPFG voting for it, while proxy advisors were split (Glass Lewis against, ISS for). The defeat highlights growing resistance to overtly political ESG proposals and signals firms will scrutinize activist demands for governance and reputational risk.

IceCure Medical highlighted its ProSense® liquid‑nitrogen cryoablation system at the CIRSE 2025 Annual Meeting, presenting three independent breast‑cancer studies, a trial on abdominal‑wall endometriosis, and an honorary lecture on breast‑oncology de‑escalation. Hands‑on training attracted strong physician interest, and a dedicated CIRSE focus session underscored growing demand for minimally invasive breast‑cancer treatments. Key data from the PRECICE, ICE3, and endometriosis studies demonstrated safety, significant tumor reduction, and pain relief, supporting ProSense®’s role as a cost‑effective, office‑based alternative to surgery and positioning IceCure for expanded global adoption.

The CAIA Association and Franklin Templeton have signed a multi‑year strategic partnership announced at Abu Dhabi Finance Week. The collaboration will guide Franklin Templeton staff through the CAIA Charter program, sponsor global CAIA Chapter events, continue title sponsorship of the “Capital Decanted” podcast, co‑create an Islamic‑Finance micro‑credential launching in 2026, and co‑author research on the Gulf’s evolution into a private‑capital hub. Both firms aim to strengthen education, professional standards, and industry innovation amid rapid shifts in alternative‑investment markets.

CVS Health outlined a growth plan that leverages its Aetna, Caremark, Pharmacy and Health‑Care Delivery businesses to deliver best‑in‑class execution, transform consumer experience and become the partner of choice. The company revised its full‑year 2025 financial guidance—revenues ≥ $400 bn, adjusted EPS $6.60‑$6.70—and provided initial 2026 targets, aiming for a mid‑teens adjusted EPS compound annual growth rate through 2028. CVS also launched an AI‑native “Engagement as a Service” platform to unify and simplify health‑care interactions across its ecosystem.

TotalEnergies and Galp have signed a strategic partnership reshaping Namibia’s offshore licences. TotalEnergies will acquire a 40 % operated interest in PEL 83 (Mopane discovery) and carry 50 % of Galp’s exploration and appraisal CAPEX, to be repaid from future cash flows. Galp will receive a 10 % participating interest in PEL 56 (Venus discovery) and 9.39 % in PEL 91. A two‑year program will drill three wells, aiming to de‑risk Mopane and achieve a final investment decision for Venus by 2026. The transaction, pending Namibian approvals, closes in 2026.

Stellantis and Bolt have signed a non‑binding MOU to explore large‑scale Level 4 driverless vehicle deployment across Europe. The partnership will use Stellantis’ AV‑Ready Platforms™ – the eK0 medium van and STLA Small – integrated into Bolt’s ride‑hailing network. Trials begin in 2026, with pilot production targeted for 2029, supporting Bolt’s goal of 100,000 autonomous vehicles by 2035, subject to regulatory approvals and definitive agreements.

ITT Inc. announced a public offering of 7 million shares at $167 each, with a 30‑day option for an additional 1.05 million shares, expecting net proceeds of about $1.14 billion. Proceeds will largely fund the planned acquisition of SPX FLOW, Inc., with surplus allocated to general corporate purposes, debt reduction, and strategic investments. Lead underwriters include Goldman Sachs and UBS, supported by multiple other banks. The offering, filed under ITT’s automatic shelf registration, reflects investor confidence in the company’s growth and the strategic synergy of the SPX FLOW acquisition.

.Align Technology announced a new Invisalign option that uses solid, laser‑welded occlusal blocks to achieve mandibular advancement for Class II malocclusions in patients aged 10‑16. Integrated with iTero scanners, exocad CAD/CAM design, and SmartTrack™ material, the system streamlines workflow, improves comfort and compliance, and delivers predictable biomechanics. Initially rolled out in Thailand and soon across Asia‑Pacific markets, analysts project the product could capture up to 12 % of the global functional‑appliance market by 2028, creating a multi‑million‑dollar revenue opportunity for Align.

Ascentage Pharma (NASDAQ: AAPG) reported four‑year Phase II data for olverembatinib in TKI‑resistant/intolerant chronic‑phase CML. Median event‑free survival was 21.2 months versus 2.9 months for best available therapy (P = 0.0159). Responses favored olverembatinib (85% CHR, 38% CCyR, 30% MMR). Safety was acceptable, with 7% vascular‑occlusion events and some grade ≥3 hematologic toxicities. The drug is approved in China and covered by the national reimbursement list; global rights depend on a Takeda option, and three Phase III registrational studies are underway.